Full-Time

Global Product Planner

Fixed Term

Posted on 5/30/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$78.6k - $146k/yr

+ Bonus

Indianapolis, IN, USA

Hybrid

Hybrid role: up to 2 days/week work-from-home; on-site required in Indianapolis.

Category
Operations & Logistics (2)
,
Required Skills
Inventory Management
SAP Products
Data Analysis
Requirements
  • Bachelor’s Degree in Business or related field
  • 5 years of experience in logistics, marketing, production, inventory control or purchasing functions with an international focus
  • Highly proficient in materials management and supply chain data analysis
  • Supporting tools include SAP & OMP
  • Excellent problem solving and negotiation skills to impact the status quo and influence decisions to achieve business decisions
  • Strong expertise in stakeholder management and excellent communication skills
  • Project management skills
Responsibilities
  • Develops global supply plan based on affiliate forecasts and GSC strategic guidance; delivers supply plans to Manufacturing and supplier partners; works with external suppliers to ensure agreed plans are met; in case of exception, works with partners to resolve situations with the least disruption to customers; monitors cycle time, critical batches and optimization of planning parameter settings to avoid destruction costs or stock outs; monitors schedule adherence and discusses if below target during Supply Review meetings (Sales and Operations Planning); monitors system alerts for potential / actual supply issues throughout the global network; makes recommendations to provide timely resolution with minimum impact to customers; works with IBL/IPM to define regional/country product allocations in case of bottleneck; keeps Regions / Affiliates / BAs informed as to potential and actual product bottlenecks
  • Manages inventories at global distribution centers to ensure high service level to customers at lowest possible costs (inventory level, distribution cost, write-offs)
  • Supports Life Cycle Management for complex and strategically critical product launches, conversions and phase outs; controls launch dates to ensure product availability in due time; controls timely clearance of discontinued products to minimize scrap costs
  • Responsible for ongoing optimization and accuracy of master data settings for planning and supply relevant to direct delivery and replenishment processes throughout global and local systems per guidelines established by the GSC governance
  • Manages affiliate inventories, replenishment plans for globally managed products; responsible for direct delivery support out of regional warehouses; replenishes Affiliate inventory levels to ensure end-customer service meets targets; manages service levels at the lowest possible cost (inventory level, distribution cost, write-offs)
  • Develops or gathers data and reports needed to optimize and support planning processes such as Annual Planning or Sales and Operations Planning
  • Sub-project management for defined task packages with budget responsibility; may independently analyze moderately complex problems, develop concepts, describe the requirements of the department and support the implementation of solutions
  • Independent execution of process and system analyses; initiation and implementation of improvement measures, including the reporting system, execution of complicated system tests, consulting and training of the system users and the presentation of best practices; analysis of particularly complex data sets
  • Business travel less than 10%

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • CE-marked pTau217 expands Alzheimer's testing beyond specialist memory clinics across Europe.
  • PathAI acquisition strengthens AI-driven pathology and companion diagnostics workflows in 2026.
  • CT-388 gives Roche a credible entry into the obesity market.

What critics are saying

  • Eli Lilly and Biogen/Eisai already dominate Alzheimer's testing and treatment pull-through.
  • Swiss franc strength and patent expirations are pressuring reported sales and cash flow.
  • Novo Nordisk and Eli Lilly set an extremely high bar for CT-388 performance.

What makes Roche unique

  • Roche unites diagnostics, medicines, and digital pathology under one commercial roof.
  • Founded in Basel in 1896, Roche built deep global clinical trust.
  • Elecsys runs on Roche cobas instruments, creating standardized testing across care settings.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.